# Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations

> **NCT04695925** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Li Zhang, MD** · enrollment: 294 (actual)

## Conditions studied

- Non-small Cell Carcinoma
- EGFR Gene Mutation

## Interventions

- **DRUG:** Osimertinib
- **DRUG:** Pemetrexed
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT04695925
- **Lead sponsor:** Li Zhang, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-29
- **Primary completion:** 2025-11-01
- **Final completion:** 2027-12-30
- **Target enrollment:** 294 (ACTUAL)
- **Last updated:** 2025-10-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04695925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04695925, "Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04695925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*